We are live on ! Find out more
HAE icon

Haemonetics

175 hedge funds and large institutions have $1.95B invested in Haemonetics in 2014 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 67 increasing their positions, 64 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $1.78B → $1.95B (+$165M)

1.72% more ownership

Funds ownership: 105.42%107.15% (+1.7%)

5% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 64

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

9% less funds holding

Funds holding: 192175 (-17)

44% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 39

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $78K

Holders
175
Holders Change
-17
Holders Change %
-8.85%
% of All Funds
5.03%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
22
Increased
67
Reduced
64
Closed
39
Calls
Puts
$78K
Net Calls
-$78K
Net Calls Change
+$890K

HAE Hedge Fund Activity: Q2 2014 in Review

175 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q2 2014, worth a combined $1.95B — up 9.2% from $1.78B a quarter earlier.

Sellers outnumbered buyers: 39 funds closed out of HAE and 22 opened new positions — a net loss of 17 holders — while 64 trimmed existing stakes and 67 added.

The largest buyer was Westwood Holdings Group, opening a new position worth an estimated $45M. The largest seller was Champlain Investment Partners, exiting entirely with an estimated $37.1M sold.

  • 175 institutional investors held Haemonetics (HAE) as of Q2 2014, down from 192 in Q1 2014.
  • Funds reported $1.95B of Haemonetics stock for Q2 2014, up 9.2% quarter-over-quarter.
  • 22 funds opened new Haemonetics positions in Q2 2014 and 39 closed out, a net change of -17 holders.
  • The largest Haemonetics buyer in Q2 2014 was Westwood Holdings Group, an estimated $45M added.
  • The largest Haemonetics seller in Q2 2014 was Champlain Investment Partners, an estimated $37.1M sold.

Based on aggregated 13F filings for Q2 2014.